| Primary |
| Product Used For Unknown Indication |
64.3% |
| Pain |
24.3% |
| Analgesic Therapy |
3.1% |
| Back Pain |
2.9% |
| Breakthrough Pain |
1.6% |
| Arthralgia |
0.6% |
| Fibromyalgia |
0.5% |
| Neck Pain |
0.4% |
| Neuralgia |
0.4% |
| Osteoarthritis |
0.3% |
| Pain In Extremity |
0.2% |
| Depression |
0.2% |
| Drug Abuse |
0.2% |
| Blood Pressure |
0.2% |
| Arthritis |
0.2% |
| Insomnia |
0.2% |
| Anxiety |
0.1% |
| Migraine |
0.1% |
| Muscle Spasms |
0.1% |
| Headache |
0.1% |
|
| Inadequate Analgesia |
15.4% |
| Drug Ineffective |
14.8% |
| Application Site Rash |
10.3% |
| Nausea |
10.1% |
| Rash |
5.9% |
| Application Site Irritation |
5.2% |
| Product Adhesion Issue |
4.5% |
| Drug Effect Decreased |
4.4% |
| Application Site Reaction |
3.3% |
| Application Site Pruritus |
3.1% |
| Vomiting |
2.9% |
| Pain |
2.6% |
| Headache |
2.6% |
| Application Site Vesicles |
2.5% |
| Dizziness |
2.4% |
| Wrong Technique In Drug Usage Process |
2.4% |
| Somnolence |
2.3% |
| Feeling Abnormal |
2.0% |
| Skin Irritation |
1.8% |
| Extra Dose Administered |
1.5% |
|
| Secondary |
| Product Used For Unknown Indication |
41.0% |
| Pain |
28.3% |
| Back Pain |
6.9% |
| Breakthrough Pain |
3.4% |
| Analgesic Therapy |
2.8% |
| Fibromyalgia |
2.6% |
| Arthralgia |
2.6% |
| Symphysiolysis |
2.3% |
| Neck Pain |
1.9% |
| Osteoarthritis |
1.3% |
| Neuralgia |
1.0% |
| Pain In Extremity |
1.0% |
| Anxiety |
0.9% |
| Arthritis |
0.8% |
| Muscle Spasms |
0.7% |
| Insomnia |
0.6% |
| Intervertebral Disc Degeneration |
0.6% |
| Depression |
0.5% |
| Convulsion |
0.4% |
| Spinal Osteoarthritis |
0.4% |
|
| Inadequate Analgesia |
31.6% |
| Drug Ineffective |
11.6% |
| Nausea |
8.8% |
| Product Adhesion Issue |
6.2% |
| Extra Dose Administered |
6.1% |
| Pain |
5.6% |
| Vomiting |
4.5% |
| Somnolence |
4.1% |
| Wrong Technique In Drug Usage Process |
3.7% |
| Application Site Rash |
2.0% |
| Application Site Vesicles |
2.0% |
| Rash |
1.9% |
| Tremor |
1.9% |
| Unevaluable Event |
1.7% |
| Drug Effect Decreased |
1.6% |
| Feeling Abnormal |
1.6% |
| Headache |
1.6% |
| Palpitations |
1.3% |
| Product Quality Issue |
1.3% |
| Skin Irritation |
1.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
47.2% |
| Pain |
10.3% |
| Rheumatoid Arthritis |
5.6% |
| Urinary Tract Infection |
3.6% |
| Crohn's Disease |
3.5% |
| Back Pain |
3.0% |
| Hypertension |
2.9% |
| Multiple Myeloma |
2.6% |
| Osteoporosis |
2.6% |
| Analgesic Therapy |
2.4% |
| Prophylaxis |
2.0% |
| Constipation |
1.8% |
| Grand Mal Convulsion |
1.8% |
| Abnormal Behaviour |
1.7% |
| Anxiety |
1.7% |
| Gastrooesophageal Reflux Disease |
1.7% |
| Nausea |
1.7% |
| Neuralgia |
1.5% |
| Diabetes Mellitus |
1.4% |
| Dyspepsia |
1.4% |
|
| Somnolence |
8.3% |
| Vomiting |
8.3% |
| Urinary Tract Infection |
6.9% |
| Blood Creatine Phosphokinase Increased |
5.6% |
| Convulsion |
5.6% |
| Diarrhoea |
5.6% |
| Drug Ineffective |
5.6% |
| Renal Failure Acute |
5.6% |
| Sepsis |
5.6% |
| Dehydration |
4.2% |
| Drug Abuse |
4.2% |
| Eye Pain |
4.2% |
| Hypercalcaemia |
4.2% |
| Nausea |
4.2% |
| Pain |
4.2% |
| Tardive Dyskinesia |
4.2% |
| Weight Decreased |
4.2% |
| Weight Increased |
4.2% |
| Anaemia |
2.8% |
| Back Pain |
2.8% |
|
| Interacting |
| Product Used For Unknown Indication |
32.3% |
| Back Pain |
16.9% |
| Convulsion |
6.2% |
| Anxiety |
5.4% |
| Blood Pressure Increased |
5.4% |
| Depression |
5.4% |
| Muscle Spasms |
5.4% |
| Urinary Tract Infection |
5.4% |
| Pain |
4.6% |
| Addison's Disease |
1.5% |
| Arthralgia |
1.5% |
| Breast Cancer |
1.5% |
| Colitis |
1.5% |
| Crohn's Disease |
1.5% |
| Inflammation |
1.5% |
| Blood Cholesterol Increased |
0.8% |
| Breakthrough Pain |
0.8% |
| Cancer Pain |
0.8% |
| Hypertension |
0.8% |
| Musculoskeletal Chest Pain |
0.8% |
|
| Vomiting |
33.3% |
| Balance Disorder |
16.7% |
| Suicidal Ideation |
16.7% |
| Nausea |
8.3% |
| Dizziness |
4.2% |
| Drug Interaction |
4.2% |
| Joint Swelling |
4.2% |
| Product Taste Abnormal |
4.2% |
| Pyrexia |
4.2% |
| Supraventricular Tachycardia |
4.2% |
|
